News
-
PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
-
Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
-
Disclosure of transactions in own shares from May 18 to May 22, 2026
-
Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
-
Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
-
Vertical Announces Grant of Options
-
Wi2Wi Corporation Announces First Quarter 2026 Financial Results (Unaudited)
-
Imagine Health Achieves Teaching Facility Status Through University of Calgary Faculty Partnership
-
CCL Industries Inc. Announces Renewal of Normal Course Issuer Bid and Approval of Automatic Securities Purchase Plan
-
Dateline Appoints Alvarez & Marsal to Manage Colosseum Development
-
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
-
Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
-
Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
-
Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
-
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors